Rahm A, Hackbarth J, Muller M, Pfeiffer J, Gampp H, Petersenn F
Int J Mol Sci. 2023; 24(18).
PMID: 37762145
PMC: 10530285.
DOI: 10.3390/ijms241813842.
Su S, Sun J, Wang Y, Xu Y
Handb Exp Pharmacol. 2021; 267:139-166.
PMID: 33829343
DOI: 10.1007/164_2021_455.
Shah R, Stonier P
Ther Adv Drug Saf. 2018; 9(8):475-493.
PMID: 30364900
PMC: 6199680.
DOI: 10.1177/2042098618780854.
Zhang Y, Colenso C, El Harchi A, Cheng H, Witchel H, Dempsey C
Biochem Pharmacol. 2016; 113:24-35.
PMID: 27256139
PMC: 4959829.
DOI: 10.1016/j.bcp.2016.05.013.
Li H, Kim H, Kim H, Shin S, Jung W, Ha K
Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(7):713-21.
PMID: 27030392
DOI: 10.1007/s00210-016-1232-8.
Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells.
Lin K, Liu Y, Xu B, Gao J, Fu Y, Chen Y
Acta Pharmacol Sin. 2013; 34(6):847-58.
PMID: 23524574
PMC: 4002887.
DOI: 10.1038/aps.2012.176.
Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.
Jehle J, Ficker E, Wan X, Deschenes I, Kisselbach J, Wiedmann F
Br J Pharmacol. 2012; 168(5):1215-29.
PMID: 23061993
PMC: 3594678.
DOI: 10.1111/bph.12002.
PKC-dependent activation of human K(2P) 18.1 K(+) channels.
Rahm A, Gierten J, Kisselbach J, Staudacher I, Staudacher K, Schweizer P
Br J Pharmacol. 2011; 166(2):764-73.
PMID: 22168364
PMC: 3417503.
DOI: 10.1111/j.1476-5381.2011.01813.x.
hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.
Staudacher I, Wang L, Wan X, Obers S, Wenzel W, Tristram F
Naunyn Schmiedebergs Arch Pharmacol. 2010; 383(2):119-39.
PMID: 21120454
DOI: 10.1007/s00210-010-0583-9.
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.
Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, Erdal H
Naunyn Schmiedebergs Arch Pharmacol. 2010; 381(5):385-400.
PMID: 20229012
DOI: 10.1007/s00210-010-0496-7.
The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.
Gessner G, Macianskiene R, Starkus J, Schonherr R, Heinemann S
Eur J Pharmacol. 2010; 632(1-3):52-9.
PMID: 20097192
PMC: 2835770.
DOI: 10.1016/j.ejphar.2010.01.010.
Apoptosis induction by doxazosin and other quinazoline alpha1-adrenoceptor antagonists: a new mechanism for cancer treatment?.
Kyprianou N, Vaughan T, Michel M
Naunyn Schmiedebergs Arch Pharmacol. 2009; 380(6):473-7.
PMID: 19904527
PMC: 5451152.
DOI: 10.1007/s00210-009-0462-4.
The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
Gierten J, Ficker E, Bloehs R, Schweizer P, Zitron E, Scholz E
Naunyn Schmiedebergs Arch Pharmacol. 2009; 381(3):261-70.
PMID: 19777211
DOI: 10.1007/s00210-009-0454-4.
Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213.
Cheng Y, Dai D, Dai Y
Acta Pharmacol Sin. 2009; 30(8):1099-106.
PMID: 19597524
PMC: 4006683.
DOI: 10.1038/aps.2009.104.
The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.
Tang Q, Li Z, Li W, Guo J, Sun H, Zhang X
Br J Pharmacol. 2008; 155(3):365-73.
PMID: 18574455
PMC: 2567890.
DOI: 10.1038/bjp.2008.261.
Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
Gierten J, Ficker E, Bloehs R, Schlomer K, Kathofer S, Scholz E
Br J Pharmacol. 2008; 154(8):1680-90.
PMID: 18516069
PMC: 2518462.
DOI: 10.1038/bjp.2008.213.
Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin.
Scherer D, von Lowenstern K, Zitron E, Scholz E, Bloehs R, Kathofer S
Naunyn Schmiedebergs Arch Pharmacol. 2008; 378(1):73-83.
PMID: 18458880
DOI: 10.1007/s00210-008-0289-4.
The effect of amiodarone pretreatment on survival of mice with cocaine toxicity.
Dewitt C, Cleveland N, Dart R, Heard K
J Med Toxicol. 2007; 1(1):11-8.
PMID: 18072097
PMC: 3550010.
DOI: 10.1007/BF03160899.
State dependent dissociation of HERG channel inhibitors.
Stork D, Timin E, Berjukow S, Huber C, Hohaus A, Auer M
Br J Pharmacol. 2007; 151(8):1368-76.
PMID: 17592502
PMC: 2189824.
DOI: 10.1038/sj.bjp.0707356.
Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation.
Diller D, Hobbs D
J Comput Aided Mol Des. 2007; 21(7):379-93.
PMID: 17549583
DOI: 10.1007/s10822-007-9122-2.